Insider · CIK 0001388000
James Noble
Files at LVTX (LAVA Therapeutics NV). First filing -, latest -.
James Noble files SEC Form 4 as director at LVTX (LAVA Therapeutics NV). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Noble has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | LVTX LAVA Therapeutics NV | DDisposition to issuer Share Options (Right to Buy)derivative | -33,390 | $0.00 | $0 | 0 | Nov 17, 2025 |
| Feb 13, 2025 | LVTX LAVA Therapeutics NV | AGrant or award Common Shares (Right to Buy)derivative | +33,390 | $0.00 | $0 | 33,390 | Feb 18, 2025 |
Questions about James Noble
Answered from the filings on this page, as of the latest one.
Is James Noble buying or selling?
James Noble has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Noble's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Noble has 0.
Where does James Noble file Form 4?
James Noble has filed Form 4 at LVTX (LAVA Therapeutics NV). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.